 |
|
|
| |
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With Chronic HCV Infection and Moderate to Severe
Renal Impairment: An Integrated Analysis
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 San Francisco
Eric Lawitz1, Edward Gane2, Meghan Sise3, Philippe J Zamor4, Marcelo Persico5, Eric M Yoshida6, Manal Abunimeh7, David Pugatch7, Yao Yu7, Preethi Krishnan7, Federico J Mensa7, Stanislas Pol8
1Texas Liver Institute, University of Texas Health, San Antonio, Texas, United States; 2Liver Unit, Auckland City Hospital, Auckland, New Zealand; 3Department of Medicine/Nephrology, Massachusetts General Hospital, Boston, Massachusett s, United States; 4Carolinas Medical Center, Charlotte,
North Carolina, United States; 5Internal Medicine and Hepatology Unit, University of Salerno, Italy; 6University of British Columbia, Vancouver, British Columbia, Canada; 7AbbVie Inc., North Chicago, Illinois, United States; 8Groupe Hospitalier Cochin-Saint Vincent De Paul, Paris, France
|
| |
|
|
|
|
|
